Clinical significance of MPL mutations in essential thrombocythemia: Analysis of the PT-1 cohort.

Clinical significance of MPL mutations in essential thrombocythemia: Analysis of the PT-1 cohort.

Opis bibliograficzny
Główni autorzy:	Beer, P, Campbell, P, Erber, W, Scott, L, Bench, A, Bareford, D, Bridget, W, Wheatley, K, Buck, G, Harrison, C, Green, A
Format:	Conference item
Wydane:	2007

Podobne zapisy

MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.
od: Beer, P, i wsp.
Wydane: (2008)

Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy.
od: Campbell, P, i wsp.
Wydane: (2009)

Bone Marrow Fibrosis and Diagnosis of Essential Thrombocythemia Reply to J. Thiele et al
od: Campbell, P, i wsp.
Wydane: (2009)

The medical research council PT1 trial in essential thrombocythemia.
od: Green, A, i wsp.
Wydane: (2004)

Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes.
od: Wilkins, B, i wsp.
Wydane: (2008)

JAK2 V617F mutation identifies a biologically distinct subtype of essential thrombocythemia which resembles polycythemia vera.
od: Green, A, i wsp.
Wydane: (2005)

Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort.
od: Campbell, P, i wsp.
Wydane: (2012)

MPL S505C enhances driver mutations at W515 in essential thrombocythemia
od: Varghese, LN, i wsp.
Wydane: (2021)

MPL S505C enhances driver mutations at W515 in essential thrombocythemia
od: Leila N. Varghese, i wsp.
Wydane: (2021-11-01)

MPL Y252H and MPL F126fs mutations in essential thrombocythemia: Case series and review of literature
od: Ahmed G. Elsayed, i wsp.
Wydane: (2019-03-01)

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
od: Harrison, C, i wsp.
Wydane: (2005)

Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia
od: Leonardo Caires dos Santos, i wsp.
Wydane: (2011-12-01)

MPL gene mutation is a possible risk factor for thrombosis in patients with essential thrombocythemia in Japan
od: Chiho Furuya, i wsp.
Wydane: (2023-12-01)

Familial Essential Thrombocythemia Associated with MPL W515L Mutation in Father and JAK2 V617F Mutation in Daughter
od: Adrian P. Trifa, i wsp.
Wydane: (2014-01-01)

Genomics of clonal evolution in a rare essential thrombocythemia with coexisting Type 2 CALR and MPL S204P mutations
od: Jing Wang, i wsp.
Wydane: (2023-12-01)

Clinical Manifestation of Calreticulin Gene Mutations in Essential Thrombocythemia without Janus Kinase 2 and MPL Mutations: A Chinese Cohort Clinical Study
od: Chao Sun, i wsp.
Wydane: (2016-01-01)

Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia
od: Kun Liu, i wsp.
Wydane: (2009-10-01)

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.
od: Campbell, P, i wsp.
Wydane: (2005)

Mutations and thrombosis in essential thrombocythemia
od: Paola Guglielmelli, i wsp.
Wydane: (2021-04-01)

Prevalence of JAK2 V617F, CALR, and MPL W515L Gene Mutations in Patients with Essential Thrombocythemia in Kurdistan Region of Iraq
od: Bestoon Muhammad Saeed, i wsp.
Wydane: (2021-03-01)

Nonfamilial, MPL S505N-Mutated Essential Thrombocythaemia
od: Ruth Morrell, i wsp.
Wydane: (2013-01-01)

Alterations of Signaling Pathways in Essential Thrombocythemia with Calreticulin Mutation
od: Hui W, i wsp.
Wydane: (2021-08-01)

Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000–2018
od: Mónica Mejía-Ochoa, i wsp.
Wydane: (2019-06-01)

Classification of Philadelphia Translocation-Negative Myeloproliferative Neoplasms: Its Impact on Data From Clinical Trials Reply
od: Campbell, P, i wsp.
Wydane: (2009)

Emerging treatments for essential thrombocythemia
od: Okoli S, i wsp.
Wydane: (2011-12-01)

Occurrence of a paroxysmal nocturnal hemoglobinuria clone in an essential thrombocythemia: a link between <i>PIGV</i> and <i>MPL</i>
od: Alexej Knaus, i wsp.
Wydane: (2022-01-01)

Retinal neovascularization in the setting of -mutation positive essential thrombocythemia
od: Stanton P Heydinger, i wsp.
Wydane: (2023-08-01)

Essential Thrombocythemia
od: Kanchanee Janwanitsthaporn
Wydane: (2002-08-01)

Essential thrombocythemia
od: Brière Jean B
Wydane: (2007-01-01)

Ruxolitinib for the Treatment of Essential Thrombocythemia
od: Arief Gunawan, i wsp.
Wydane: (2018-08-01)

Philadelphia-positive acute lymphoblastic leukemia in a case of MPL p.(W515L) variant essential thrombocythemia: case report and literature review
od: Jiale Ma, i wsp.
Wydane: (2022-08-01)

Dynamics of mutations in patients with essential thrombocythemia treated with imetelstat
od: Elisabeth Oppliger Leibundgut, i wsp.
Wydane: (2020-07-01)

Acute Lymphoblastic Leukemia Arising in CALR Mutated Essential Thrombocythemia
od: Stephen E. Langabeer, i wsp.
Wydane: (2016-01-01)

Calreticulin Mutated Essential Thrombocythemia Presenting as Acute Coronary Syndrome
od: Bassel Nazha, i wsp.
Wydane: (2015-01-01)

The presence of the factor V Leiden and the prothrombin G20210A polymorphism does not appear to influence the risk of thrombosis in essential thrombocythaernia: results of a nested case control study
od: Robinson, S, i wsp.
Wydane: (2008)

Shortened telomeres in essential thrombocythemia: clinicopathological and treatment correlations
od: Samah Alimam, i wsp.
Wydane: (2018-06-01)

Neuromyotonia in association with essential thrombocythemia.
od: Benito-León, J, i wsp.
Wydane: (2000)

Neurological disorders in essential thrombocythemia
od: Segolene Billot, i wsp.
Wydane: (2011-12-01)

Myelofibrotic transformation in essential thrombocythemia
od: Juergen Thiele, i wsp.
Wydane: (2009-03-01)

Thromboembolic complication in Essential Thrombocythemia
od: Zahra Mozaheb
Wydane: (2012-11-01)